Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2668-2676

  Ross, Jeffrey S ^a,b   Wang, Kai ^b   Sheehan, Christine E ^a   Boguniewicz, Ann B ^a   Otto, Geoff ^b   Downing, Sean R ^b   Sun, James ^b   He, Jie ^b   Curran, John A ^b   Ali, Siraj ^b   Yelensky, Roman ^b   Lipson, Doron ^b   Palmer, Gary ^b   Miller, Vincent A ^b   Stephens, Philip J ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b FOUNDATION MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSIC E CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; PROTEIN MCL 1; SMAD4 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; PARAFFIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CCND1 GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA SEQUENCE; ERBB2 GENE; EXON; FEMALE; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENE FUSION; GENE MUTATION; GENE OVEREXPRESSION; GRB7 GENE; HUMAN; HUMAN TISSUE; INTRON; LIVER METASTASIS; MAJOR CLINICAL STUDY; MAP2K4 GENE; MCL1 GENE; MEN1 GENE; PRIORITY JOURNAL; RELAPSE; SMAD4 GENE; BREAST TUMOR; CYTOCHEMISTRY; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG CARCINOMA; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; MUTATION RATE; PAGET NIPPLE DISEASE; PATHOLOGY; TISSUE FIXATION; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; EXONS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTOCYTOCHEMISTRY; HUMANS; MIDDLE AGED; MUTATION; MUTATION RATE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PARAFFIN EMBEDDING; RECEPTOR, ERBB-2; TISSUE FIXATION;

EID: 84878083237     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0295     Document Type: Article

References (45)

1. Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol 2009;16:204-15.
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
3. Tavassoli FA. Lobular neoplasia: evolution of its significance and morphologic spectrum. Int J Surg Pathol 2010;18:174S-7S.
4. Venkitaraman R. Lobular neoplasia of the breast. Breast J 2010; 16:519-28.
5. Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, et al. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the sameway? analysis of an institutional database over a 10-year period. Ann Surg Oncol 2012; 19:1107-14.
6. Jung SY, Jeong J, Shin SH, Kwon Y, Kim EA, Ko KL, et al. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study. BMC Cancer 2010;10:664.
7. O'Malley FP. Lobular neoplasia: morphology, biological potential and management in core biopsies. Mod Pathol 2010;23(Suppl 2):S14-25.
8. Rakha EA, Ellis IO. Lobular breast carcinoma and its variants. Semin Diagn Pathol 2010;27:49-61.
9. Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 2012;133:713-23.
10. Jacobs M, Fan F, Tawfik O. Clinicopathologic and biomarker analysis of invasive pleomorphic lobular carcinoma as compared with invasive classic lobular carcinoma: an experience in our institution and review of the literature. Ann Diagn Pathol 2012;16:185-9.
11. Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade-and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010; 220:45-57.
12. O'Toole SA, Selinger CI, Millar EK, Lum T, Beith JM. Molecular assays in breast cancer pathology. Pathology 2011;43:116-27.
13. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486: 405-9.
14. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.
15. Morrogh M, Andrade VP, Giri D, Sakr RA, Paik W, Qin LX, et al. Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Res Treat 2012;132:641-52.
16. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4.
17. Wang K, Yelensky R, Dogan S, Borsu L, Frampton GM, Lipson D, et al. An evaluation of next-generation sequencing for diagnostic use in cancer care [abstract]. 2012 Meeting of Association of Molecular Pathology. J Mol Diagn 2012;14:637-748.
18. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, Macdonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013;63:920-6.
19. Frampton GM, Downing S, Brennan K, Donahue A, White E, Garcia L, et al.. Validation of a comprehensive NGS-based cancer genomic assay for clinical use. In: Proceedings of the AACC Annual Meeting 2012; 2012 Jul 15-19; Los Angeles, CA. Presentation nr C-19.
20. Lipson D, He J, Yelensky R, Miller V, Sheehan C, Brennan K, et al. Nextgeneration sequencing of FFPE breast cancers demonstrates high concordance with FISH in calling HER2 amplifications and commonly identifies additional clinically relevant genomic alterations. Cancer Res 2012;72(Suppl 24):PD02-07.
21. Yoder BJ, Wilkinson EJ, Massoll NA. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J 2007;13:172-9.
22. Bertucci F, Orsetti B, Nègre V, Finetti P, Rougé C, Ahomadegbe JC, et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008;27:5359-72.
23. Xie ZM, Li LS, Laquet C, Penault-Llorca F, Uhrhammer N, Xie XM, et al. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but not diffuse gastric cancer. Cancer 2011;117:3112-7.
24. Tang D, Xu S, Zhang Q, Wang J, Lu K, Song Y, et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple negative breast cancer. Med Oncol 2012;29:526-33.
25. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68.
26. Monhollen L, Morrison C, Ademuyiwa FO, Chandrasekhar R, Khoury T. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. Histopathology 2012;61:365-77.
27. Yu J, Dabbs DJ, Shuai Y, Niemeier LA, Bhargava R. Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics. Am J Clin Pathol 2011; 136:88-97.
28. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18:4910-8.
29. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525-6.
30. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224-37.
31. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12:57-61.
32. Trowe T, Boukouvala S, Calkins K, Cutler RE Jr, Fong R, Funke R, et al. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 2008;14: 2465-75.
33. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25-38.
34. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006;354:2619-21.
35. Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 2007;26:5023-7.
36. Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 2011;74:139-44.
37. Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS ONE 2011;6:e26760.
38. Katoh M, Katoh M. Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenomic recombination hotspot around the PPP1R1B-ERBB2-GRB7 amplicon. Int J Oncol 2004;24:757-63.
39. Saito M, Kato Y, Ito E, Ishikawa K, Doi A, Kumazawa K, et al. Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene. FEBS Lett 2012;586:1708-14.
40. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009;462:1005-10.
41. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003;63:132-9.
42. Wolf-Yadlin A, Kumar N, Zhang Y, Hautaniemi S, Zaman M, Kim HD, et al. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol 2006;2:54-8.
43. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 2004;279:24505-13.
44. Finn RD, Mistry J, Tate J, Coggill P, Heger A, Pollington JE, et al. The Pfam protein families database. Nucleic Acids Res 2010;38: D211-22.
45. Hunter S, Jones P, Mitchell A, Apweiler R, Attwood TK, Bateman A, et al. InterPro in 2011: new developments in the family and domain prediction database. Nucleic Acids Res 2012;40:D306-12.